Kiniksa Pharmaceuticals International, plc KNSA
95.05 USD 0.00 (+0.00%)
Regular-session close
95.10 +0.05 +0.05%
Pre-market · Nov 19, 8:42 AM ET
94.36 Day range 97.01
37.02 52-week range 99.31
- YTD
- +130.42%
- 1 year
- +130.26%
News
benzinga.com TD Cowen Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $115 TD Cowen analyst Nicholas Lorusso maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $100 to $115.
defenseworld.net Kiniksa Pharmaceuticals International, plc $KNSA Stock: Aberdeen Group plc Reduces Stake Aberdeen Group plc decreased its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) by 13.9% during the third quarter, according to the company in its most recent…
defenseworld.net 74,458 Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Fisher Asset Management LLC Fisher Asset Management LLC trimmed its position in Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) by 18.7% during the third quarter, according to its most recent 13F filing with the SEC.…benzinga.com JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122 JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $107 to $122.
benzinga.com Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101 Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $90 to $101.
benzinga.com Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102 Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $99 to $102.
benzinga.com Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110 Wells Fargo analyst Yanan Zhu maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $87 to $110.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
benzinga.com Crude Oil Moves Lower; Corning Earnings Top Views U.S. stocks mostly rose Tuesday: S&P 500 +0.5%, Nasdaq +1.1%, while Dow slipped. Oil fell 1.5%; Corning beat Q3 estimates.
benzinga.com Pentair, JetBlue Airways, Hawkins And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed as Dow slips 0.1%; Pentair jumps 9.8% on strong Q3 results and raised FY26 sales guidance, with several stocks rallying.
benzinga.com Kiniksa Pharmaceuticals Q3 2026 Earnings Call Transcript Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock…benzinga.com Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $980.000M-$995.000M to $1.045B-$1.050B vs $996.102M Est Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $980.000 million-$995.000 million to $1.045 billion-$1.050 billion vs $996.102 million estimate.
benzinga.com Kiniksa Pharmaceuticals Q3 EPS $0.56 Beats $0.37 Estimate, Sales $285.970M Beat $260.611M Estimate Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.37 by 51.35 percent. This is a 143.48 percent increase over…
